Browsing items tagged “Spain | EVERSANA”

Spain’s Pharmaceutical Financing Committee Focuses on Increasing Competition, Strengthening Therapeutic Positioning Reports

Region: EUROPE | Type: Policy | Keywords: #biosimilars #capf #drugevaluation #generics #hta #innovation #irp #newindications #pricesetting #referencepricing #therapeuticpositioningreports PRICENTRIC BRIEF: The Advisory Committee for the Financing of Pharmaceutical Provisions (CAPF) under the National Health Service (SNS) has put forth a series of proposals to address, in the medium term, the pricing and financing strategies of medicines in Spain The below plan for CAPF will be addressed over the next two years […]

Spain Must “Go Further, Bet on R&D, Innovation, Knowledge,” Says Farmaindustria President Sellés

Country: SPAIN | Region: EUROPE | Type: Policy | Keywords: #access #affordability #clinicaltrials #covid19 #farmaindustria #industry #investment #r&d #sns PRICENTRIC BRIEF: In its pharmaceutical industry proposals for economic and social reform, the National Trade Association of the Spanish-Based Pharmaceutical Industry (Farmaindustria) is requesting more investment in research and production in Spain Sellés explained that investment in R&D and innovation and public-private collaboration are crucial to be “faster in finding pharmacological and more […]

Biosimilars Saved Spain 2,400 Million Euros Between 2009 and 2020

Country: SPAIN | Region: EUROPE | Type: Biosimilar | Keywords: #inflammatorydiseases #monoclonalantibodies #oncology #regulation #sefh PRICENTRIC BRIEF: The Spanish Society of Hospital Pharmacists (SEFH) calculated that Spain has saved more than 2,400 million euros between 2009 and 2020 through the introduction of biosimilars for the treatment of inflammatory diseases and cancer In the article, published in the May/June issue of the journal Farmacia Hospitalaria, Dr. Miguel Ángel Calleja, former […]

Spain Authorizes Centralized Purchase of 391 Million Euros Worth of Medicines

Country: SPAIN | Region: EUROPE | Type: Regulation | Keywords: #antianemicagents #antineoplasticagents #centralizedpurchase #immunomodulatoryagents #immunosuppressants #sns PRICENTRIC BRIEF: The Council of Ministers has authorized the centralized purchase of 391 million euros worth of medicines under which manufacturers will be selected to supply different active principles at an estimated savings of 128 million euros for Spain’s National Health System (SNS) Spain is looking primarily at immunosuppressants for autoimmune diseases […]